(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 10.31%
-2.17% $ 1.800
Live Chart Being Loaded With Signals
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 3 673.00 |
Średni wolumen | 30 533.00 |
Kapitalizacja rynkowa | 7.70M |
EPS | $0 ( 2024-04-18 ) |
Następna data zysków | ( $-0.250 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.420 |
ATR14 | $0.0140 (0.76%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Clowes Howard | Buy | 2 250 | Stock Option (Right to Buy) |
2024-02-22 | Lafrance Norman D. | Buy | 24 073 | Stock Option (Right to Buy) |
2024-02-22 | Hedrick Marc H | Buy | 94 012 | Stock Option (Right to Buy) |
2024-02-22 | Sims Andrew John Hugh Macintyre | Buy | 18 933 | Stock Option (Right to Buy) |
2024-02-22 | Lenk Robert P | Buy | 2 250 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
99.12 |
Last 94 transactions |
Buy: 2 283 640 | Sell: 1 020 583 |
Plus Therapeutics Inc Korelacja
10 Najbardziej negatywne korelacje | |
---|---|
BNIXU | -0.904 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Plus Therapeutics Inc Finanse
Annual | 2023 |
Przychody: | $4.91M |
Zysk brutto: | $4.17M (84.84 %) |
EPS: | $-4.24 |
FY | 2023 |
Przychody: | $4.91M |
Zysk brutto: | $4.17M (84.84 %) |
EPS: | $-4.24 |
FY | 2022 |
Przychody: | $224 000 |
Zysk brutto: | $-488 000 (-217.86 %) |
EPS: | $-11.91 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.010 |
Financial Reports:
No articles found.
Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej